Intelligent Pharma Partners: Pathology AI Needs a New Business Model
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for
2018 Global AI-based Pathology Solutions in Immuno-oncology Technology Innovation Award
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc.
Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual
WHITE PAPER: Using Artificial Intelligence To Determine Patient Response To Immunotherapy
Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better
POSTER: Methodology for Designing and Validating Computational Pathology Scores for Immune Cell Clustering in Tumor Biopsy Samples
Abstract Background Immune cell clustering is commonly observed in histopathology images. As the frequency and nature of immune cell clustering may represent biological phenomena critical to
POSTER: Comparison of Multiplexed Imaging Mass Cytometry with Monoplex Immunohistochemistry in FFPE Tissue
Abstract Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and the tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches
